Neuroendocrine and Adrenal Tumors

Neuroendocrine and Adrenal Tumors: Biochemical, Histopathologic and Genetic Studies

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04432532

Acronym

NETAT

Enrollment

Registered

2020-06-16

Start date

2025-12-01

Completion date

2028-01-01

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenal Tumor, Neuroendocrine Tumors

Brief summary

This is a prospective study of rare neuroendocrine and adrenal tumors. Subjects will be enrolled via informed consent, and blood and/or saliva and tissue will be collected. This is designed to work in conjunction with IRB#831990 which is a retrospective protocol. The University of Pennsylvania will be a contributing site with the University of Michigan as the coordinating site for the A5 alliance, a multi-institutional collaborative designed to study neuroendocrine and adrenal tumors.

Interventions

OTHERNo intervention

There are no interventions

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Inclusion criteria

* diagnosed with neuroendocrine and/or an adrenal tumor

Exclusion criteria

* pregnant women * prisoners * people under the age of 18

Design outcomes

Primary

Measure	Time frame
Survival	10 years

Secondary

Measure	Time frame	Description
Tumor Recurrence	10 years	We want to record recurrences in our patient population

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026